Thermo Fisher Scientific Q1 Earnings Call Highlights

Key Points

• Thermo Fisher reported a "strong start" to 2026 with Q1 revenue up 6% to $11.01 billion and adjusted EPS up 6% to $5.44, and it raised full‑year guidance to $47.3–$48.1 billion in revenue and $24.64–$25.12 in adjusted EPS.
• It closed the approximately $9 billion acquisition of Clario (adding $30 million of revenue and $0.01 of adjusted EPS in Q1), which management says strengthens clinical research and AI‑enabled trial data capabilities and contributed about $900 million revenue and $0.32 EPS to the updated outlook.
• The company returned about $3.2 billion to shareholders (including $3 billion of buybacks and a 10% dividend increase) while noting roughly 80 basis points of margin headwind from tariffs/FX and mixed end‑market demand—strong bioproduction and clinical research but softness in analytical instruments and certain diagnostics—plus an inflation "placeholder" in its guidance.

Thermo Fisher Scientific NYSE: TMO reported what executives described as a “strong start” to 2026, posting first-quarter revenue growth and raising its full-year outlook after closing the acquisition of clinical trial technology provider Clario late in the quarter.

First-quarter results and end-market trends

Chairman and CEO Marc Casper said the company’s end markets “progress[ed] in line with our expectations” as Thermo Fisher continued executing its growth strategy and integrating recent acquisitions.

For the first quarter, Casper said revenue increased 6% to $11.01 billion and adjusted operating income rose 6% to $2.4 billion. Adjusted operating margin was 21.8%, and adjusted earnings per share increased 6% to $5.44. CFO Jim Meyer added that GAAP EPS was $4.43, up 11% from the prior-year quarter.

By end market, Casper outlined the following performance for the quarter:

• Pharma and biotech: Mid-single-digit growth, driven by strength in bioproduction, clinical research, and the research and safety market channel.
• Academic and government: Low-single-digit decline, reflecting “muted macro conditions” in the U.S. and China.
• Industrial and applied: Flat growth, led by chromatography and mass spectrometry as well as the research and safety market channel.
• Diagnostics and healthcare: Mid-single-digit decline, though the company delivered “another quarter of strong growth” in transplant diagnostics.

Meyer said reported revenue growth included 1% organic growth, 3% from acquisitions, and a 2% tailwind from foreign exchange. He also noted the quarter had one less selling day versus the year-ago period, which reduced organic revenue growth by about one percentage point. By geography, Meyer said North America grew low single digits, Europe was flat, and Asia Pacific was flat, with China declining low single digits.

Clario acquisition and capital deployment

Thermo Fisher closed the acquisition of Clario in late March. Casper called Clario “a market leader in digital endpoint data solutions” and said it was “highly complementary” to Thermo Fisher’s clinical research capabilities, helping enable deeper clinical insights and improve drug development productivity.

Meyer said Clario was not included in the company’s previous guidance and contributed $30 million of revenue and $0.01 of adjusted EPS in the first quarter. He also said Thermo Fisher completed the acquisition for “approximately $9 billion plus potential future performance-based payments,” and that Clario is now part of the Laboratory Products and Biopharma Services segment.

On capital return, Casper said the company repurchased $3 billion of shares during the quarter and increased its dividend by 10%. Meyer quantified total capital returned to shareholders in the quarter at $3.2 billion, including $3 billion of share buybacks and about $160 million of dividends.

Segment performance and tariff-related pressure

Meyer provided details across Thermo Fisher’s four business segments:

• Life Sciences Solutions: Reported revenue increased 13% and organic revenue grew 1%, led by “another quarter of excellent organic growth” in bioproduction. Adjusted operating margin was 36.2%, up 60 basis points year over year.
• Analytical Instruments: Reported revenue was flat and organic revenue declined 2%. Meyer attributed the performance to “muted demand for instruments” from academic and government customers in the U.S. and China. Adjusted operating margin fell to 20.7%, down 250 basis points, with Meyer saying the majority of the margin change reflected the “expected impacts of tariffs and related FX.”
• Specialty Diagnostics: Reported revenue declined 1% and organic revenue declined 3%, reflecting one less selling day and a strong year-over-year comparison, according to Meyer. Adjusted operating margin rose to 27.4%, up 90 basis points, with growth led by transplant diagnostics.
• Laboratory Products and Biopharma Services: Reported revenue increased 7% and organic revenue grew 4%, led by clinical research and the research and safety market channel. Adjusted operating margin was 12.9%, down 10 basis points year over year.

At the corporate level, Meyer said adjusted operating margin declined 10 basis points year over year, including “approximately 80 basis points of headwind from tariffs and related FX versus the prior year.” He also said Thermo Fisher’s productivity funded strategic investments and helped offset mix pressure and tariff-related headwinds.

Innovation, AI collaborations, and customer demand signals

Casper highlighted new product launches across the portfolio, including the Thermo Scientific Glacios 3 Cryo-TEM with AI-enabled workflows; the TSQ Certis triple quadrupole mass spectrometer; the Niton XL5e handheld XRF analyzer; the Gibco CTS Compleo Fill and Finish System for cell therapy manufacturing; and the FluidEase Pro ClipTip Electronic Pipette.

Casper also pointed to strategic collaborations, including work with NVIDIA to develop AI-enabled workflow solutions for scientific instrumentation. He said Thermo Fisher also formed a collaboration with SHL Medical to expand U.S. drug product manufacturing capabilities, leveraging its Ridgefield, New Jersey sterile fill-finish site to provide integrated sterile fill-finish and device assembly solutions.

On clinical research, Casper said the business delivered “strong revenue and authorizations growth” and that the company’s accelerated drug development offering is translating into “strong performance and share gain.” In response to questions, Casper said clinical research had “an excellent quarter,” with a “nice step up in organic growth” and improving conditions as the biotech funding environment strengthens.

Casper said early customer feedback on Clario has been positive, noting customers are “very excited about the technology that Clario has” and the potential to bring major endpoints together more easily in clinical trials.

On AI more broadly, Casper said Thermo Fisher believes AI will improve returns on investment in drug development, which he said could increase pipeline activity and enhance funding interest in biotech. He said the company sees AI as a “meaningful positive” and expects it to strengthen Thermo Fisher’s competitive advantage. Casper also told analysts Thermo Fisher would host an analyst day on the morning of May 20 in New York.

Raised 2026 guidance, with inflation placeholder and quarterly phasing

Thermo Fisher raised its full-year 2026 guidance to reflect first-quarter execution and the Clario acquisition. Casper said the company increased revenue guidance to $47.3 billion to $48.1 billion from $46.3 billion to $47.2 billion, while maintaining an assumption of 3% to 4% organic revenue growth. He said adjusted EPS guidance was raised to $24.64 to $25.12 from $24.22 to $24.80.

Meyer said at the midpoint, updated guidance includes $900 million higher revenue, 20 basis points of additional margin expansion, and $0.37 higher adjusted EPS compared with the prior outlook. He said Clario increased revenue guidance by $900 million and added $0.32 of adjusted EPS net of financing costs. Thermo Fisher expects about $660 million of net interest expense for the year and an adjusted tax rate of 11.5%.

Meyer said the company included an assumption for potentially higher inflation later in the year, describing it as a “placeholder” given volatility in oil prices and the risk of inflation the company might not be able to fully mitigate within a year. He said the earliest impacts were visible in “supply chain logistics and transportation,” and that teams are actively working on offsets.

On quarterly cadence, Meyer said organic revenue growth is expected to be about 3% in the second quarter and that adjusted EPS in Q2 is expected to be $0.25 to $0.30 higher than Q1. In response to questions about the year’s expected ramp, management pointed to selling-day impacts and phasing, including a “meaningfully different revenue phasing profile in pharma services” that results in stronger growth in the second half, according to Meyer.

About Thermo Fisher Scientific NYSE: TMO

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.